Medplus Health Services Ltd (MEDPLUS) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company demonstrated strong performance, highlighted by a significant net addition of 182 stores in the quarter, bringing the total network to 5,112 stores.
- Revenue growth was robust, driven by a 15.6% year-on-year increase in Pharmacy operations and a notable 10%+ Same-Store Sales Growth (SSSG), attributed to a revised store-level incentive structure and improved product availability from new warehouses.
- Private label sales continued to be a key contributor, constituting 22.2% of total revenues, with private label pharma GMV share reaching 18.9%, a substantial increase from 7.9% in the prior year's first quarter.
- The Diagnostics segment showed strong momentum, with revenue growing to INR 326.7 million and operating EBITDA margin expanding significantly to 15.5%, up from INR 22.1 million in the same quarter last year.
- The company's financial health improved, reflected in a reduction of the networking capital cycle to 53 days, driven by inventory management efficiencies and the expansion of the franchise model.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.